Pushing Past the Blockade: Advancements in T Cell-Based Cancer Immunotherapies
Successful cancer immunotherapies rely on a replete and functional immune compartment. Within the immune compartment, T cells are often the effector arm of immune-based strategies due to their potent cytotoxic capabilities. However, many tumors have evolved a variety of mechanisms to evade T cell-me...
Enregistré dans:
Auteurs principaux: | Jessica Waibl Polania, Emily C. Lerner, Daniel S. Wilkinson, Alexandra Hoyt-Miggelbrink, Peter E. Fecci |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Frontiers Media S.A.
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/808b5813dcf74fa597cb5e25097d8f85 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Targeting Tumor-Associated Macrophages in Cancer Immunotherapy
par: Amy J. Petty, et autres
Publié: (2021) -
Engineered CAR-Macrophages as Adoptive Immunotherapies for Solid Tumors
par: Christopher Sloas, et autres
Publié: (2021) -
Vitamin C, From Supplement to Treatment: A Re-Emerging Adjunct for Cancer Immunotherapy?
par: Léonce Kouakanou, et autres
Publié: (2021) -
Adoptive chimeric antigen receptor T cell (CAR-T) and Treg cell-based immunotherapies: Frontier therapeutic aspects in cancers
par: Mehran Bahraini, et autres
Publié: (2021) -
Armored CAR T-Cells: The Next Chapter in T-Cell Cancer Immunotherapy
par: Hawkins ER, et autres
Publié: (2021)